Abbott Laboratories (ABT) Holdings Lifted by Bank of Nova Scotia

The Philadelphia Trust Company holds 601,417 shares with $23.10M value, up from 571,866 last quarter. First Command Financial Services Inc. raised its position in shares of Abbott Laboratories by 10.2% in the 1st quarter. The stock increased 0.62% or $0.32 during the last trading session, reaching $52.08. About 4.09M shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since September 20, 2016 and is uptrending. Also, the current price highlights a discount of 29.15% to analysts’ high consensus price target. Zacks has “Hold” rating and $16 target. About 1.34 million shares traded. It has outperformed by 21.64% the S&P500. Shares for $26,482 were sold by Watkin Jared. $10,677 worth of Inphi Corporation (NYSE:IPHI) was sold by Torten Ron.

Among 29 analysts covering BP (NYSE:BP), 19 have Buy rating, 2 Sell and 8 Hold. Therefore 28% are positive. JB Hunt Trans had 40 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Goldman Sachs given on Friday, November 13. Fincl Bank Of Mellon reported 2.06 million shares. The company was maintained on Wednesday, October 21 by Deutsche Bank. The firm has “Market Perform” rating by Cowen & Co given on Friday, October 14. Morgan Stanley reaffirmed an “equal weight” rating on shares of Abbott Laboratories in a report on Monday, July 10th. The firm has “Buy” rating given on Tuesday, March 15 by Jefferies. Cowen & Co maintained the shares of ABT in report on Tuesday, August 15 with “Buy” rating. RBC Capital Markets has “Outperform” rating and $51 target.

A number of research analysts recently weighed in on the company. Stockholders of record on Friday, October 13th will be issued a $0.265 dividend.

Since May 1, 2017, it had 0 insider buys, and 8 sales for $14.61 million activity. Accern also assigned media stories about the healthcare product maker an impact score of 45.4527935034291 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days. 79 funds opened positions while 223 raised stakes. 18,500 were reported by Hillsdale Mngmt. Newman Dignan & Sheerar owns 7,170 shares for 0.17% of their portfolio. Lord Abbett And invested in 663,520 shares. Moors And Cabot owns 8,845 shares. Panagora Asset Inc holds 0% or 14,250 shares. Blb&B Advisors Lc invested in 70,423 shares. Citigroup Inc has invested 0% of its portfolio in Endocyte, Inc. Following the transaction, the insider now directly owns 143,154 shares in the company, valued at approximately $7,157,700. State Treasurer State Of Michigan reported 28,576 shares. Brown Brothers Harriman & reported 1,048 shares or 0% of all its holdings. The New York-based First Manhattan Co has invested 0.02% in the stock. Stifel reported 215,634 shares stake. Veritas Invest Management Llp invested in 2,030 shares or 0.01% of the stock. During the same period in the prior year, the firm posted $0.55 EPS. IPHI’s profit will be $3.38M for 125.59 P/E if the $0.08 EPS becomes a reality. (NASDAQ:ECYT). Meeder Asset reported 0% in Endocyte, Inc.

Abbott Laboratories has a consensus outperform rating from 20 Wall Street analysts, and the number of shares now sold short amount to at least 0.94% of shares outstanding. Therefore 61% are positive. The company was maintained on Monday, July 10 by BMO Capital Markets. The firm earned “Outperform” rating on Wednesday, August 5 by RBC Capital Markets. The company has a market cap of $90.16 billion, a P/E ratio of 72.68 and a beta of 1.06. As per Thursday, April 27, the company rating was maintained by RBC Capital Markets. The stock of NanoString Technologies Inc (NASDAQ:NSTG) earned “Buy” rating by Leerink Swann on Wednesday, August 5. BMO Capital Markets reissued a “hold” rating and set a $48.00 price target on shares of Abbott Laboratories in a research report on Tuesday, July 11th. The legal version of this piece can be viewed at The stock has “Hold” rating by Credit Suisse on Thursday, June 1. It also reduced its holding in Wyndham Worldwide Corp (NYSE:WYN) by 127,000 shares in the quarter, leaving it with 250,000 shares, and cut its stake in Asanko Gold Inc (NYSEMKT:AKG).

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 20th. Moreover, Bridgeway Capital Management Inc has 0.02% invested in the company for 52,598 shares. After having $0.62 EPS previously, Abbott Laboratories’s analysts see 4.84% EPS growth.

Investors sentiment decreased to 0.88 in 2016 Q4. Its up 0.91, from 0.76 in 2016Q3. It turned negative, as 83 investors sold ABT shares while 496 reduced holdings. Kanaly Trust Co raised its stake in Abbott Laboratories by 3.7% in the third quarter. Broderick Brian C’s holdings in Abbott Laboratories were valued $5,311,000 as of its latest disclosure with the securities and exchange commission. Redmile Gru Limited Liability Co reported 937,957 shares. Winfield Associate reported 0.05% of its portfolio in Abbott Laboratories (NYSE:ABT). Nomura initiated the shares of BP in report on Friday, March 18 with “Neutral” rating. Independence Tru Company, Tennessee-based fund reported 15,860 shares. Virtu Financial Ltd stated it has 0.07% in Abbott Laboratories (NYSE:ABT). $34,240 worth of Abbott Laboratories (NYSE:ABT) shares were sold by Contreras Jaime. Martingale Asset LP holds 0.01% or 9,262 shares in its portfolio. Berry Plastics Group Inc (NYSE:BERY) was raised too. Parallax Volatility Advisers LP reported 441,032 shares stake. Numeric Ltd Liability Company accumulated 86,756 shares. Weatherly Asset Mngmt Limited Partnership reported 29,897 shares stake. Oakworth Capital Incorporated has 0.21% invested in Abbott Laboratories (NYSE:ABT). Janus Management Limited Company holds 0.01% or 330,248 shares in its portfolio. Nordea Invest Management Ab reported 715,477 shares or 0.07% of all its holdings.

Since March 31, 2017, it had 0 insider buys, and 2 selling transactions for $60,722 activity.

Leave a Reply

Your email address will not be published. Required fields are marked *